Science
Targeting prostacyclin to inhibit platelet activation; MRD-tailored myeloma maintenance; AREG and HSC function in DNA damage repair deficiency and aging
2023-11-02
In this week's episode we'll see how targeting the prostacyclin receptor is a promising strategy for regulating hemostasis and thrombosis. Then, we'll learn how new evidence indicates that the progression rate is low in MRD-negative myeloma patients who discontinue post-transplant lenalidomide and dexamethasone maintenance therapy after 2 years. Finally we'll discuss how amphiregulin from leptin receptor-positive niche cells in the bone marrow mediates crosstalk between the niche and hematopoietic stem cells under conditions of DNA repair deficiency and aging.
More Episodes
2020-04-09
2020-04-02
2020-03-26
2020-03-19
2020-03-12
2020-03-05
2020-02-27
2020-02-20
2020-02-13
2020-02-06
2020-01-30
2020-01-23
2020-01-16
2020-01-09
2020-01-02
2019-12-10
2019-12-10
2019-12-10
Get this podcast on your
phone, FREE
